{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:56:07Z","timestamp":1793472967742,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T00:00:00Z","timestamp":1437955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journalofpsychiatricresearch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jpsychires.2015.07.015","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T05:50:07Z","timestamp":1437630607000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial"],"prefix":"10.1016","volume":"69","author":[{"given":"Huafang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niufan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2015.07.015_bib1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A\u00a0rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/NDT.S43404","article-title":"Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options","volume":"10","author":"Chue","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib5","first-page":"1199","article-title":"Comparison study between risperidone long-acting injectable and risperidone tablets in patients with schizophrenia","volume":"12","author":"Kamijima","year":"2009","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","article-title":"Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.jpsychires.2015.07.015_bib7","doi-asserted-by":"crossref","first-page":"e88049","DOI":"10.1371\/journal.pone.0088049","article-title":"Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Kishi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02354306","article-title":"A\u00a0new five factor model of schizophrenia","volume":"65","author":"Lindenmayer","year":"1994","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib12","series-title":"Guideline for Schizophrenia Prophylaxis and Treatment [M]","author":"Chinese Medical Association","year":"2007"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib13","first-page":"297","article-title":"Clinical evaluation of blonanserin for schizophrenia \u2013 a randomized study comparing blonanserin with risperidone","volume":"11","author":"Miura","year":"2008","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib14","first-page":"2059","article-title":"Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib15","first-page":"845","article-title":"Dopamine-serotonin antagonist:receptor binding profile of a novel antipsychotic blonanserin","volume":"11","author":"Murasaki","year":"2008","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib16","series-title":"Schizophrenia (Update). Clinical Guidelines, CG82","author":"National Institute for Health and Care Excellence","year":"2009"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib18","series-title":"Handbook of Psychiatric Measures","first-page":"485","article-title":"Psychotic disorders measures","author":"Perkins","year":"2000"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-642-25758-2_6","article-title":"5-HT(2C) agonists as therapeutics for the treatment of schizophrenia","volume":"213","author":"Rosenzweig-Lipson","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib21","series-title":"Stahl's Essential Psychopharmacology. Neuroscientific Basis and Practical Applications","first-page":"339","author":"Stahl","year":"2010"},{"key":"10.1016\/j.jpsychires.2015.07.015_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/JCP.0b013e3182825bce","article-title":"Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia","volume":"33","author":"Tateno","year":"2013","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib23","first-page":"1263","article-title":"Pharmacological characteristics of blonanserin","volume":"10","author":"Une","year":"2007","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","article-title":"Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial","volume":"33","author":"Yang","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2015.07.015_bib26","first-page":"69","article-title":"Epidemiological investigation on mental disorders in 7 areas of China","volume":"31","author":"Zhang","year":"1998","journal-title":"Chin. J. Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395615002083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395615002083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T18:55:29Z","timestamp":1537469729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395615002083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":22,"alternative-id":["S0022395615002083"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2015.07.015","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2015.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}